TME-Targeted Drug Evaluation in Glioblastoma
Our Organoid 2.0 preserved intact immune, vascular, and hypoxic components of GBM for >4 weeks, enabling TME-directed drug testing impossible in standard models.
Challenge
Glioblastoma (GBM) is one of the most treatment-resistant cancers, partly due to its complex TME including hypoxic regions, vascular components, and immune infiltrates. Standard organoid models lose these components within days.
Approach
GBM PDO 2.0 models were established using our ALI culture system. TME preservation was validated by H&E and IF staining (Nestin, Olig2, S100B). Drug efficacy against the HIF-2alpha pathway was evaluated using a tumor killing assay by FACS.
Results:
Intact immune, vascular, and hypoxic TME components preserved for >4 weeks. HIF-2alpha pathway inhibition demonstrated measurable tumor killing quantified by FACS.
Implication
Enables preclinical testing of TME-targeted therapies in GBM—a capability not available in any conventional model system.